Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010; 16(36): 4504-4514
Corresponding Author of This Article
Mohammad Abdollahi, Professor, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Copyrightcopy;2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 28, 2010; 16(36): 4504-4514 Published online Sep 28, 2010. doi: 10.3748/wjg.v16.i36.4504
A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease
Roja Rahimi, Mohammad Reza Shams-Ardekani, Mohammad Abdollahi
Roja Rahimi, Mohammad Reza Shams-Ardekani, Faculty of Traditional Medicine, Tehran University of Medical Sciences, Tehran 1417614411, Iran
Mohammad Abdollahi, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran
Author contributions: Rahimi R searched the literature, read the papers, gathered the data and drafted the manuscript; Shams-Ardekani MR read the papers and left comments and points; Abdollahi M conceived, supervised, and reviewed the entire study and edited the manuscript.
Correspondence to: Mohammad Abdollahi, Professor, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran. firstname.lastname@example.org
Telephone: +98-21-88611883 Fax: +98-21-88611883
Received: February 27, 2010 Revised: April 1, 2010 Accepted: April 8, 2010 Published online: September 28, 2010
The etiology of inflammatory bowel disease (IBD) is not yet known, but many factors such as defects in the immune system, oxidative stress, microbial content in the gastrointestinal tract, nuclear factor (NF)-κB, nitric oxide (NO), cyclooxygenase-2 (Cox-2), and leukotriene B4 (LB4) are thought to play a role in its pathogenesis. In traditional Iranian medicine (TIM), several medicinal plants are thought to be effective for the treatment of IBD. In this study, information on all of these remedies were derived from all available old sources such as documents or notes and books and were added to the information derived from modern medical databases covering all in vitro, in vivo and clinical trials. For some of these plants, only one or two mechanisms of action have been found such as in Cassia fistula, Lepidium sativum, and Bunium persicum. However, for some plants various mechanisms of action are known. For example, Commiphora mukul is effective in IBD due to its immunomodulatory, antioxidant, and antibacterial properties and it decreases NF-κB, NO and Cox-2. Another herb, Plantago ovata, has immunomodulatory, antioxidant, anti-inflammatory and wound healing activities and decreases NO and LB4. Considering the mechanisms of action of these plants, the combination of some of them may be useful because of their many mechanisms of action such as Pistacia lentiscus, Bunium persicum, Solanum nigrum, Plantago ovata, Boswellia, Solanum nigrum, Plantago ovata and Commiphora mukul. For some of the herbal products used in TIM such as oleogum resin from Commiphora myrrha, seeds of Ocimum basilicum, seeds of Linum usitatissimum, gum resin of Dracaena cinnabari, seeds of Plantago major, seeds of Lallementia royleana, and seeds of Allium porrum, there is no or not enough studies to confirm their benefits in IBD. It is suggested that an evaluation of the effects of these plants on different aspects of IBD should be performed.
Citation: Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010; 16(36): 4504-4514
Inflammatory bowel disease (IBD) refers to two chronic diseases that cause inflammation of the intestines: ulcerative colitis (UC) and Crohn’s disease (CD). The etiology of IBD is unclear. The most accepted hypothesis currently implicates a combination of one or more of the following factors: immune dysregulation (caused by genetic or environmental factors), abnormal gastrointestinal (GI) tract luminal factors (such as microorganisms constituting the GI tract flora), oxidative stress, and defects in the GI mucosal barrier that allow luminal factors to penetrate into the mucosa[1,2].
In our previous paper, we reviewed all medicinal plants used worldwide for the treatment of IBD by including all in vitro, in vivo, and clinical studies that examined medicinal plants for the treatment of IBD. Added to that information, there is information and data that are only found in documents, notes, or books by traditional Iranian medicine (TIM) scientists. In TIM, there is a GI disease known as “Zahir” which seems to be identical to IBD regarding the explained symptoms of the disease. Zahir is defined as tenesmus of the rectum during defecation followed by secretion of mucosa and bloody diarrhea. Various natural remedies have been used in TIM for IBD. These remedies have been used for many years by Iranian physicians such as Rhazes and Avicenna for the treatment of IBD in humans. Different mechanisms of action have been described in traditional Iranian publications accounting for the usefulness of these plants in IBD, which include anti-inflammatory, antiulcer, wound healing, and antidiarrheal activities[5,6]. In the present work, these remedies are revised individually and possible evidence of their efficacy in modern medicine is reviewed. For this purpose, electronic databases including Pubmed, Scopus, Embase, and Google Scholar were searched for each of the plants in TIM and all retrieved articles were examined to obtain studies giving any in vitro, in vivo, or clinical evidence of the efficacy of these herbs in the treatment of IBD. The retrieved studies directly evaluated these herbs on IBD animal models or humans, or indirectly surveyed their efficacy on the mechanisms involved in the pathogenesis of IBD.
FACTORS INVOLVED IN THE PATHOGENESIS OF IBD
There is evidence of defective responses in both the innate and the adaptive immune systems in IBD. The behavior of the cells mediating innate immunity such as neutrophils, macrophages, dendritic cells, and natural killer cells are altered, and defective mucosal T helper (Th) cell responses and greater expression of cytokines such as interleukin (IL)-1-β, IL-6, IL-12, tumor necrosis factor α (TNF-α) and interferon (IFN)-γ were demonstrated in patients with IBD[8,9]. Recent meta-analyses confirmed the efficacy of anti-TNF-α drugs for induction of remission in UC but did not confirm them for induction of response and remission in CD.
Oxidative stress is a potential etiological and/or triggering factor for IBD, because the damaging effects of reactive oxygen molecules have been well established in the inflammation process[12-14]. Although some conflicting results exist, it seems that patients with IBD demonstrate excessive oxidized molecules compared with healthy control subjects in a variety of organic systems (e.g. GI tract, blood, and respiratory system). Recent studies have shown decreased total antioxidant capacity and increased reactive oxygen molecules in patients with IBD[13-15].
Some studies have suggested a role for the microbial content of the GI tract in the pathogenesis of IBD. The disease occurs in areas of the GI tract with the highest concentrations of luminal bacteria. Normal, nonpathogenic enteric bacteria can induce chronic intestinal inflammation in genetically susceptible hosts with defective immunoregulation, bacterial clearance, or mucosal barrier function. It has been shown that the concentration of intestinal bacteria in IBD is higher than normal and increases progressively with severity of the disease[17-19]. Probiotics have been found to be useful in the management of irritable bowel syndrome and pouchitis. Antibacterials and probiotics have been demonstrated to be effective in UC via modification of the gut bacterial flora[22,23]. However, current meta-analyses have only confirmed the efficacy of antibiotics for CD and failed to demonstrate the efficacy of probiotics in maintaining remission and preventing clinical and endoscopic recurrence in CD.
These proteins are a family of structurally related eukaryotic transcription factors that promote the expression of over 150 genes, many of which play important roles in the regulation of inflammation and apoptosis. Excess or inappropriate activation of nuclear factor (NF)-κB has been observed in human IBD[27,28]. Thus, inhibitors of NF-κB can be used as a treatment strategy for the management of IBD.
Nitric oxide (NO) is a short-life molecule produced by the enzyme known as NO synthase (NOS), in a reaction that converts arginine and oxygen into citrulline and NO. There are three isoforms of the enzyme: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). Interestingly, NO has both beneficial and detrimental roles in the body. It seems that constitutive forms of NO synthase (cNOS) including nNOS and eNOS are critical to normal physiology, while inhibition of these enzymes may cause cellular damage. On the other hand, induction of iNOS causes injury; therefore, specific inhibition of this enzyme can be beneficial. Three key observations confirm the detrimental role of iNOS in inflammation. Firstly, since large quantities of NO are produced by iNOS relative to the two cNOS isoforms, excess NO may contribute to inflammation through nitrosation, oxidative damage, and enhanced inflammatory cytokines. Secondly, expression patterns of iNOS correlate with prolonged inflammation. Thirdly, inhibition of iNOS results in reduced inflammation[29,30]. There is evidence that IBD is associated with an overproduction of NO by iNOS. Increased luminal and salivary NO has also been detected in IBD patients[32,33]. It was shown that inhibition of iNOS blunted dextran sulfate sodium (DSS) colitis in mice.
Cyclooxygenase-2 (Cox-2) is another involved factor in IBD acting through synthesis of prostaglandins. Thus, selective Cox-2 inhibitors, such as celecoxib, are another class of drugs that have been claimed to be effective in IBD[35,36].
Leukotriene B4 is a pro-inflammatory mediator with a role in several inflammatory diseases such as IBD. Inhibition of this mediator can reduce inflammation and ameliorate IBD.
MODERN EVIDENCE FOR THE EFFICACY OF MEDICINAL PLANTS IN TIM USED FOR THE TREATMENT OF IBD
Oleogum resin from Pistacia lentiscus (P. lentiscus) known as “Mastaki” is an efficacious remedy for the treatment of IBD in TIM. Supplementation with oleogum resin from P. lentiscus delayed the onset and progression of the disease and helped prevent weight loss in the DSS model of colitis (Tables 1[39-63] and 2[64-81]). In addition, oleogum resin inhibited the production of pro-inflammatory substances such as NO and prostaglandin E2. Western blotting and reverse transcription polymerase chain reaction (RT-PCR) analyses have shown that oleogum resin from P. lentiscus inhibited the expression of iNOS and Cox-2 at both the protein and mRNA levels. It has shown potent hydroxyl radical scavenging activity; however, it has scavenged NO and superoxide radicals very poorly (Table 1). Oleogum resin from P. lentiscus at an oral dose of 500 mg/kg produced a significant reduction in the intensity of gastric mucosal damage induced by pyloric ligation, aspirin, phenylbutazone, and reserpine in rats (Table 2). Treating CD patients with oleogum resin from P. lentiscus resulted in the reduction of TNF-α secretion (P = 0.028). Macrophage migration inhibitory factor (MIF) release was significantly increased (P = 0.026) meaning that random migration and chemotaxis of monocytes/macrophages was inhibited. No significant changes were observed in IL-6, monocyte chemotactic protein-1 (MCP-1), and intracellular antioxidant glutathione (GSH) concentrations showing that oleogum resin from P. lentiscus acts as an immunomodulator on peripheral blood mononuclear cells (PBMCs) by a TNF-α inhibitory and a MIF stimulatory activity. Another study performed on CD patients demonstrated a significant reduction in the CD activity index (CDAI) (P = 0.05) due to oleogum resin from P. lentiscus as compared to pretreatment values. Plasma IL-6 and C-reactive protein (CRP) were significantly decreased. Total antioxidant potential (TAP) was significantly increased (P = 0.036). No patient or control exhibited any side effects. A double-blind clinical trial was carried out on patients with symptomatic and endoscopically proven duodenal ulcers, to compare therapeutic responses to oleogum resin from P. lentiscus and placebo over a period of 2 wk. The results from this study demonstrated symptomatic relief in 80% of patients treated with oleogum resin from P. lentiscus and in 50% patients treated with placebo. Endoscopically proved healing occurred in 70% of patients treated with oleogum resin from P. lentiscus and in 22% patients treated with placebo. The differences between the treatments were highly significant (P < 0.01). Oleogum resin from P. lentiscus was well tolerated and did not produce side effects. This study showed that oleogum resin from P. lentiscus has an ulcer healing effect (Table 3[82-88]).
Table 1In vitro studies on plants used in traditional Iranian medicine for the treatment of inflammatory bowel disease.
↓Proliferative response of peripheral blood mononuclear cells, ↓inflammatory mediators such as IFN-δ, IL-12, TNF-α, IL-1β and NO, ↓NO production in lipopolysaccharide-activated mouse peritoneal macrophages
Ineffective in ameliorating colitis, ↑the basal and IL-1β-stimulated NF-κB activity in intestinal epithelial cells in vitro as well as reverse proliferative effects of IL-1β, hepatotoxicity effect with pronounced hepatomegaly and steatosis was observed
↓Gastric lesions induced by cold restraint stress (76.6%), indomethacin (73.8%), pyloric ligation (80.1%) and ethanol (70.6%) with equal or higher potency than omeprazole, ↓gastric secretory volume and acidity and pepsin secretion, ↑rate of healing of ulcers, ↓H(+)K(+)ATPase activity, ↓gastrin secretion
The proportion of patients in clinical remission was higher in the Boswellia serrata extract group than in the placebo group; Compared to placebo, Boswellia serrata extract treatment had no effect on histology and quality of life
Eighteen out of 20 patients treated with Boswellia gum resin showed an improvement in one or more of the parameters including stool properties, histopathology as well as scanning electron microscopy, hemoglobin, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils; In the sulfasalazine group, 6 out of 10 patients showed similar results in the same parameters, 14 out of 20 patients treated with Boswellia gum resin achieved remission, while in the case of sulfasalazine the remission rate was 4 out of 10
All tested parameters including stool properties, histopathology, scanning microscopy of rectal biopsies, and blood parameters including hemoglobin, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils improved after treatment with Boswellia serrata gum resin. The rate of remission was similar in the two studies group (82% in the Boswellia serrata group vs 75% in the sulfasalazine group)
Symptomatic relief in 80% of patients on oleogum resin from P. lentiscus and 50% in patients on placebo, endoscopically proven healing occurred in 70% of patients on oleogum resin from P. lentiscus and 22% of patients on placebo, no side effects observed
Gum resin from Commiphora mukul (C. mukul) known as “Moghl” is another natural product used in TIM for IBD[4,89]. Guggulsterone (GS), a steroid isolated from the gum resin of C. mukul, has been investigated in two models of intestinal inflammation induced in mice by trinitro-benzene sulfonic acid (TNBS) and oxazolone. The results showed that GS protects mice against the development of signs and symptoms of colon inflammation. GS effectively attenuated the severity of disease, the fecal score and colon inflammation as assessed by measuring the macroscopic and microscopic damage scores. In vitro, mechanistic studies carried out using CD4+ cells isolated from the intestinal lamina propria demonstrated that GS effectively regulates the function of effector T cells. The net biological effects resulting from exposure to GS includes attenuation of the generation of IL-2, IL-4 and IFN-γ as well as T cell proliferation (Table 1). GS blocked the NF-κB signaling pathway and attenuated DSS-induced acute murine colitis (Table 2). Several compounds in the gum resin from C. mukul have shown lipid peroxidation and Cox inhibitory activities. The anti-inflammatory effect of C. mukul gum has been studied in PBMCs and showed an inhibitory effect on the proliferative response of PBMC. Further studies on inflammatory mediators such as IFN-γ, IL-12, TNF-α, IL-1β and NO showed down-regulation, whereas no inhibition was observed in the case of the anti-inflammatory cytokine IL-10. The methanolic extract of the gum resin from C. mukul was found to inhibit NO production in lipopolysaccharide-activated mouse peritoneal macrophages. The essential oil, chloroform extract, and seven sesquiterpenoid compounds isolated from the oleogum resin of C. mukul demonstrated a wide range of inhibitory activity against both gram positive and gram negative bacteria (Table 1).
The fruit of Foeniculum vulgare (F. vulgare) known as “Razianeh” in TIM has been used for the treatment of IBD. The aqueous and organic seed extracts have shown significant antibacterial activity comparable to standard antibiotics. n-Butanol and aqueous fruit extracts of F. vulgare showed moderate radical scavenging properties in vitro (Table 1). Pretreatment with aqueous extracts of F. vulgare significantly reduced ethanol-induced gastric lesions in rats. In addition, this extract significantly reduced lipid peroxidation and increased antioxidant activity. Oral administration of F. vulgare fruit methanolic extract to mice exhibited inhibitory effects against acute and subacute inflammatory diseases and type IV allergic reactions and showed a central analgesic effect. Moreover, it significantly increased the plasma antioxidant activity and decreased lipid peroxidation (Table 2). The aqueous extract of F. vulgare showed a significant NO scavenging effect in vitro (Table 1).
The black fruit of Terminalia chebula (T. chebula) known as “Halile siah” in TIM has been used for the treatment of IBD. The aqueous extract of T. chebula has been shown to effectively modulate oxidative stress and enhance antioxidant status in the liver and kidney of aged rats. The ethanolic extract of T. chebula accelerated the rate of healing of gastric lesions induced by indomethacin and inhibited lipid peroxidation in the gastric tissue of rats (Table 2). In addition, the ethanolic extract has been tested against specific multidrug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (S. aureus) and extended spectrum β-lactamase-producing enteric bacteria and has shown broad-spectrum activity. This extract has also shown synergistic interaction with tetracycline, chloramphenicol and ciprofloxacin against S. aureus and/or Escherichia coli (E. coli). In addition, the butanol fraction of T. chebula fruit had profound growth-inhibitory activity against six intestinal bacteria, especially Clostridium perfringens and E. coli. An aqueous extract from T. chebula was found to inhibit inducible nitric oxide synthesis by decreasing iNOS protein and iNOS mRNA levels (Table 1).
The seed of Lipidium sativum known as “Tokhm taretizak” is another famous drug used in TIM for IBD. The ethanolic extract from the seed of this plant has shown significant anti-inflammatory and analgesic activities in rats. However, it has been shown to potentiate gastric ulcer induced by indomethacin in these animals (Table 2). The mechanism of action of this seed seems to be inhibition of prostaglandin synthesis.
Plantago ovata and P. psyllium
The seed isolated from Plantago ovata (P. psyllium) and P. psyllium called “Esfarzah” is also used as an effective drug in the treatment of IBD[56,90]. Dietary fiber supplementation with 5% P. ovata seeds ameliorated the development of colonic inflammation in transgenic rats as evidenced by an improvement in intestinal cytoarchitecture. This effect was associated with a decrease in some of the pro-inflammatory mediators involved in the inflammatory process such as NO, leukotriene B4, and TNF-α. The intestinal contents from fiber-treated colitis rats showed a significantly higher production of short chain fatty acids, butyrate and propionate, than non-treated colitis animals. In vitro studies revealed a synergistic inhibitory effect of butyrate and propionate on TNF-α production. A significant reduction in colonic myeloperoxidase activity and restoration of colonic glutathione levels were also shown by this supplementation in a similar study (Table 2). Mucopolysaccharides derived from the husk of P. ovata have properties beneficial for wound cleansing and wound healing. It also limits scarring (Table 1). An open label, multicenter, randomized clinical trial was conducted to compare the efficacy and safety of P. ovata seeds (10 g bid) with mesalamine (500 mg tid) in maintaining remission in UC. After 12 mo, the relapse rate was 40% (14 of 35 patients) in the P. ovata seed group, 35% (13 of 37) in the mesalamine group, and 30% (9 of 30) in the P. ovata plus mesalamine group. The results of this study showed that P. ovata seeds might be as effective as mesalamine in maintaining remission in UC (Table 3).
The fruit of Bunium persicum (B. persicum) known as “zireh kermani” is another natural product used for the treatment of IBD in TIM. It is an economically important medicinal plant growing wild in the dry regions of Iran. The essential oil of B. persicum has strong anti-bacterial effects. This property could be the result of relatively high amounts of terpinenes and cumin aldehyde in the essential oil. In addition, this essential oil has shown antioxidant properties. It was able to reduce the oxidation rate of soybean oil in the accelerated condition at 60°C (Table 1).
Fruit from Cassia fistula (C. fistula) known as “Flous” is another drug for the treatment of IBD in TIM. The only known mechanism related to the beneficial effect of this plant is its antimicrobial properties. Crude extract of C. fistula exhibited significant antimicrobial activity (Table 1).
Fruit from Cydonia oblonga known as “Beh” is also used for the treatment of IBD. This fruit has shown radical scavenging and antimicrobial activities. The phenolic extract exhibited the strongest antioxidant activity among the other extracts. The antioxidant functions of its phenolic extracts were superior to that of chlorogenic acid and ascorbic acid as standard antioxidants (Table 1).
The fruit of Solanum nigrum (S. nigrum) known as “Tajrizi” is another natural product for the treatment of IBD in TIM[4,5]. A glycoprotein isolated from this fruit [Solanum nigrum L. (SNL) glycoprotein] has demonstrated a dose-dependent inhibitory effect on NO production and free radical formation in DSS-induced colitis in mice. It exhibited a suppressive effect on the activities of NF-κB and regulated the expression of iNOS and Cox-2 in the downstream signaling pathway (Table 2). S. nigrum fruits showed effective free radical scavenging activities in the 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay which seemed to be related to the SNL glycoprotein. The SNL glycoprotein has remarkable scavenging effects on both the superoxide anion and hydroxyl radical, but exhibited slightly higher scavenging effects on the superoxide anion generated by the enzymatic hypoxanthine/xanthine oxidase system than on hydroxyl radicals generated by the Fenton reaction (Table 1). Treatment with S. nigrum extract significantly inhibited the gastric lesions induced by cold restraint stress (76.6%), indomethacin (73.8%), pyloric ligation (80.1%) and ethanol (70.6%) with equal or higher potency than omeprazole in experimental ulcer models. It also showed concomitant attenuation of gastric secretory volume, acidity and pepsin secretion in ulcerated rats. In addition, it accelerated the healing of acetic acid-induced ulcers after 7 d of treatment. Furthermore, it significantly inhibited H+K+ATPase activity and decreased gastrin secretion in the ethanol-induced ulcer model. The severity of the reaction of the ulcerogen and the reduction in ulcer size by S. nigrum extract was evident from histological findings (Table 2)[78,79].
The kernel of Juglans regia (J. regia) known as “gerdou” has been used for the treatment of IBD in TIM. Polyphenol compounds isolated from n-butanol extract of J. regia demonstrated a significant decrease in lipid peroxidation and a remarkable increase in antioxidant potential (Table 1).
Oleogum resin from Boswellia carterii (B. carterii) and Boswellia serrata (B. serrata) known as “Kondor” in TIM is another efficacious remedy for IBD[6,90]. Various studies have shown the anti-inflammatory effect of this oleogum resin (Table 2)[65,66]. Some new mono- and triterpenes isolated from this oleogum resin have exhibited NO production inhibitory activity in lipopolysaccharide-activated mouse peritoneal macrophages. The ethanol extract of this oleogum resin has immunomodulatory properties in vitro. The antimicrobial activities of the essential oil isolated from the oleogum resin of B. carterii have been demonstrated against various microorganisms including fungi, and gram-positive and gram-negative bacterial strains (Table 1). The results of a study evaluating the effectiveness of Boswellia extracts in controlled settings of DDS- or TNBS-induced colitis in mice suggested that Boswellia is ineffective in ameliorating colitis in these models. Moreover, individual boswellic acids were demonstrated to increase the basal and IL-1β-stimulated NF-κB activity in intestinal epithelial cells in vitro as well as reverse the proliferative effects of IL-1β. In addition, a hepatotoxic effect of Boswellia with pronounced hepatomegaly and steatosis was observed (Table 2). Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral B. serrata extract 400 mg three times daily for 6 wk or placebo. After 6 wk, the proportion of patients in clinical remission was higher in the B. serrata extract group than in the placebo group (P = 0.04). Compared to placebo, B. serrata extract treatment had no effect on histology and quality of life. Thirty patients with chronic colitis were randomized to receive either a preparation of the gum resin from B. serrata (900 mg daily divided in three doses for 6 wk) or sulfasalazine (3 g daily divided in three doses for 6 wk). Of 20 patients treated with Boswellia gum resin, 18 patients showed an improvement in one or more of the parameters including stool properties, histopathology as well as scanning electron microscopy, in addition to hemoglobin, serum iron, calcium, phosphorus, proteins, total leukocytes, and eosinophils. In the sulfasalazine group, 6 of 10 patients showed similar results in the same parameters. Of 20 patients treated with Boswellia gum resin, 14 achieved remission, while in the case of sulfasalazine, the remission rate was 4 of 10. In a similar study, patients with UC received either B. serrata gum resin preparation (350 mg three times daily for 6 wk) or sulfasalazine (1 g three times daily) and all tested parameters including stool properties, histopathology, scanning microscopy of rectal biopsies, blood parameters including hemoglobin, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils improved after treatment with B. serrata gum resin. The rate of remission was similar in the two studies group (82% in the B. serrata group vs 75% in the sulfasalazine group) (Table 3).
The flower and seed of various species of Althaea known as “Khatmi” in TIM have been claimed to be efficacious in IBD. The ethanol extract of Althaea officinalis demonstrated significant antibacterial activity against E. coli (Table 1). The ethanol extract of the flower of Althaea rosea showed anti-inflammatory and analgesic effects in carrageenan- or dextran-induced rat paw edema (Table 2).
Various herbal preparations have been used in TIM for the treatment of IBD. For many of the plants used in these formulations, there are various studies demonstrating their efficacy in IBD. These studies included in vitro, in vivo, and clinical trials which are summarized in detail in Tables 1-3, respectively. Table 4 briefly shows the modes of action of these plants in IBD. These medicines have shown their usefulness in IBD by different mechanisms of action including inhibiting the production of NO, Cox-2 and leukotriene B4, immunomodulatory properties, antimicrobial activities, antioxidant activities, and antiulcer and wound healing properties. As shown in Table 4, for some of these plants, only one or two mechanisms of action have been found such as in Juglans regia, Cassia fistula, Lepidium sativum, and Bunium persicum. However, in some of the plants various mechanisms of action are known. For example Commiphora mukul is effective in IBD due to its immunomodulatory, antioxidant, and antibacterial properties and it decreases NF-κB, NO and Cox-2. Another herb, Plantago ovata, has immunomodulatory, antioxidant, anti-inflammatory and wound healing activities and decreases NO and leukotriene B4. Considering the mechanisms of action of these plants, the combination of some of them may be useful due the numerous mechanisms involved in IBD, such as Pistacia lentiscus, Bunium persicum, Solanum nigrum, Plantago ovata, Boswellia, Solanum nigrum, Plantago ovata and Commiphora mukul.
Table 4 Mechanisms of action of the plants used for the treatment of inflammatory bowel disease in traditional Iranian medicine.
1Modulating immune system by effects on factors of innate immunity including neutrophils, macrophages, dendritic cells, and natural killer cells are altered and defective mucosal helper T (Th) cell responses and greater expression of cytokines such as interleukin (IL)-1-β, IL-6, IL-12, tumor necrosis factor α (TNF-α) and interferon (IFN)-γ;
2Decreasing factors involved in oxidative stress and lipid peroxidation and/or increased factors enhanced antioxidant capacity. Asterisks indicate having that kind of effect under the column heading. LB4: Leukotriene B4; NO: Nitric oxide; Cox-2: Cyclooxygenase-2; NF-κB: Nuclear factor κB.
Based on the published studies, some plants are likely to be more effective in the management of current IBD cases such as Pistacia lentiscus, Plantago ovata and Commiphora mukul. No exact relationship was found between the class of plants investigated and their efficacy which supports the hypothesis of a complicated pathogenesis of IBD.
No potential adverse events have been reported for these remedies. There is only one study showing the ineffectiveness of the gum resin from B. serrata in ameliorating colitis in mouse DSS- and TNBS-induced colitis. Moreover, this study demonstrated its hepatotoxic effect. However, other studies on gum resin from this plant have demonstrated its benefit in IBD such as inhibiting NO production, immunomodulatory properties, antimicrobial, anti-inflammatory activities[65,66], and inducing clinical remission[84,85].
For some of the herbal products used in TIM such as oleogum resin from Commiphora myrrha, seeds of Ocimum basilicum, seeds of Linum usitatissimum, gum resin from Dracaena cinnabari, seeds of Plantago major, seeds of Lallementia royleana, and seeds of Allium porrum, there are no or not enough studies to confirm their benefits in IBD. It is suggested that an evaluation of the effects of these plants on different aspects of IBD should be performed.
Peer reviewers: Inge I Depoortere, PhD, Centre for Gastroenterological Research, Gasthuisberg OandN, bus 701, Leuven 3000, Belgium; Alain L Servin, PhD, Faculty of Pharmacy, French National Institute of Health and Medical Research, Unit 756, Rue J.-B. Clément, F-922296 Châtenay-Malabry, France
S- Editor Tian L L- Editor Webster JR E- Editor Ma WH
Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, Domschke W. Recent understanding of IBD pathogenesis: implications for future therapies.Inflamm Bowel Dis. 2006;12:1068-1083.
Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis.J Dig Dis. 2007;8:171-178.
Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies.Dig Dis Sci. 2009;54:471-480.
Brown SJ, Mayer L. The immune response in inflammatory bowel disease.Am J Gastroenterol. 2007;102:2058-2069.
Ince MN, Elliott DE. Immunologic and molecular mechanisms in inflammatory bowel disease.Surg Clin North Am. 2007;87:681-696.
Elsässer-Beile U, von Kleist S, Gerlach S, Gallati H, Mönting JS. Cytokine production in whole blood cell cultures of patients with Crohn’s disease and ulcerative colitis.J Clin Lab Anal. 1994;8:447-451.
Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids.Med Sci Monit. 2007;13:PI13-PI18.
Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials.Biomed Pharmacother. 2007;61:75-80.
Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?Dig Dis Sci. 2007;52:2015-2021.
Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease.Dig Dis Sci. 1996;41:2078-2086.
Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases.Dig Dis Sci. 2004;49:1752-1757.
Buffinton GD, Doe WF. Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients.Free Radic Res. 1995;22:131-143.
Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy.Int J Med Microbiol. 2010;300:25-33.
Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M. Mucosal flora in inflammatory bowel disease.Gastroenterology. 2002;122:44-54.
Sartor RB. Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when.Curr Opin Gastroenterol. 2003;19:358-365.
Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease.Aliment Pharmacol Ther. 2004;20 Suppl 4:75-78.
Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials.Dis Colon Rectum. 2008;51:1775-1780.
Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials.Dig Dis Sci. 2008;53:1278-1284.
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis.Dig Dis Sci. 2007;52:2920-2925.
Rahimi R, Nikfar S, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission.Arch Med Sci. 2008;4:185-190.
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn's disease.Clin Ther. 2006;28:1983-1988.
Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease.Dig Dis Sci. 2008;53:2524-2531.
Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease.J Mol Med. 2004;82:434-448.
Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease.Gut. 1998;42:477-484.
Andresen L, Jørgensen VL, Perner A, Hansen A, Eugen-Olsen J, Rask-Madsen J. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis.Gut. 2005;54:503-509.
Kanwar JR, Kanwar RK, Burrow H, Baratchi S. Recent advances on the roles of NO in cancer and chronic inflammatory disorders.Curr Med Chem. 2009;16:2373-2394.
Martín MC, Martinez A, Mendoza JL, Taxonera C, Díaz-Rubio M, Fernández-Arquero M, de la Concha EG, Urcelay E. Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility.Immunogenetics. 2007;59:833-837.
Lundberg JO, Hellström PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis.Lancet. 1994;344:1673-1674.
Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, Daryani NE, Abdollahi M. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients.Ann N Y Acad Sci. 2007;1095:305-314.
Naito Y, Takagi T, Ishikawa T, Handa O, Matsumoto N, Yagi N, Matsuyama K, Yoshida N, Yoshikawa T. The inducible nitric oxide synthase inhibitor ONO-1714 blunts dextran sulfate sodium colitis in mice.Eur J Pharmacol. 2001;412:91-99.
Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.Am J Gastroenterol. 2002;97:910-914.
El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.Am J Gastroenterol. 2006;101:311-317.
Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.Gastroenterology. 1984;86:453-460.
Watt K, Christofi N, Young R. The detection of antibacterial actions of whole herb tinctures using luminescent Escherichia coli.Phytother Res. 2007;21:1193-1199.
Yoshikawa M, Morikawa T, Oominami H, Matsuda H. Absolute stereostructures of olibanumols A, B, C, H, I, and J from olibanum, gum-resin of Boswellia carterii, and inhibitors of nitric oxide production in lipopolysaccharide-activated mouse peritoneal macrophages.Chem Pharm Bull (Tokyo). 2009;57:957-964.
Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro.Clin Diagn Lab Immunol. 2005;12:575-580.
Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D. Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae).Ann Chim. 2007;97:837-844.
Shahsavari N, Barzegar M, Sahari MA, Naghdibadi H. Antioxidant activity and chemical characterization of essential oil of Bunium persicum.Plant Foods Hum Nutr. 2008;63:183-188.
Kumar VP, Chauhan NS, Padh H, Rajani M. Search for antibacterial and antifungal agents from selected Indian medicinal plants.J Ethnopharmacol. 2006;107:182-188.
Francis JA, Raja SN, Nair MG. Bioactive terpenoids and guggulusteroids from Commiphora mukul gum resin of potential anti-inflammatory interest.Chem Biodivers. 2004;1:1842-1853.
Manjula N, Gayathri B, Vinaykumar KS, Shankernarayanan NP, Vishwakarma RA, Balakrishnan A. Inhibition of MAP kinases by crude extract and pure compound isolated from Commiphora mukul leads to down regulation of TNF-alpha, IL-1beta and IL-2.Int Immunopharmacol. 2006;6:122-132.
Matsuda H, Morikawa T, Ando S, Oominami H, Murakami T, Kimura I, Yoshikawa M. Absolute stereostructures of polypodane- and octanordammarane-type triterpenes with nitric oxide production inhibitory activity from guggul-gum resins.Bioorg Med Chem. 2004;12:3037-3046.
Saeed MA, Sabir AW. Antibacterial activities of some constituents from oleo-gum-resin of Commiphora mukul.Fitoterapia. 2004;75:204-208.
Fattouch S, Caboni P, Coroneo V, Tuberoso CI, Angioni A, Dessi S, Marzouki N, Cabras P. Antimicrobial activity of Tunisian quince (Cydonia oblonga Miller) pulp and peel polyphenolic extracts.J Agric Food Chem. 2007;55:963-969.
Hamauzu Y, Yasui H, Inno T, Kume C, Omanyuda M. Phenolic profile, antioxidant property, and anti-influenza viral activity of Chinese quince (Pseudocydonia sinensis Schneid.), quince (Cydonia oblonga Mill.), and apple (Malus domestica Mill.) fruits.J Agric Food Chem. 2005;53:928-934.
Kaur GJ, Arora DS. Antibacterial and phytochemical screening of Anethum graveolens, Foeniculum vulgare and Trachyspermum ammi.BMC Complement Altern Med. 2009;9:30.
De Marino S, Gala F, Borbone N, Zollo F, Vitalini S, Visioli F, Iorizzi M. Phenolic glycosides from Foeniculum vulgare fruit and evaluation of antioxidative activity.Phytochemistry. 2007;68:1805-1812.
Baliga MS, Jagetia GC, Rao SK, Babu K. Evaluation of nitric oxide scavenging activity of certain spices in vitro: a preliminary study.Nahrung. 2003;47:261-264.
Fukuda T, Ito H, Yoshida T. Antioxidative polyphenols from walnuts (Juglans regia L.).Phytochemistry. 2003;63:795-801.
Zhou L, Satoh K, Takahashi K, Watanabe S, Nakamura W, Maki J, Hatano H, Takekawa F, Shimada C, Sakagami H. Re-evaluation of anti-inflammatory activity of mastic using activated macrophages.In Vivo. 2009;23:583-589.
Westerhof W, Das PK, Middelkoop E, Verschoor J, Storey L, Regnier C. Mucopolysaccharides from psyllium involved in wound healing.Drugs Exp Clin Res. 2001;27:165-175.
Al-Fatimi M, Wurster M, Schröder G, Lindequist U. Antioxidant, antimicrobial and cytotoxic activities of selected medicinal plants from Yemen.J Ethnopharmacol. 2007;111:657-666.
Heo KS, Lim KT. Antioxidative effects of glycoprotein isolated from Solanum nigrum L.J Med Food. 2004;7:349-357.
Aqil F, Ahmad I. Antibacterial properties of traditionally used Indian medicinal plants.Methods Find Exp Clin Pharmacol. 2007;29:79-92.
Kim HG, Cho JH, Jeong EY, Lim JH, Lee SH, Lee HS. Growth-inhibiting activity of active component isolated from Terminalia chebula fruits against intestinal bacteria.J Food Prot. 2006;69:2205-2209.
Moeslinger T, Friedl R, Volf I, Brunner M, Koller E, Spieckermann PG. Inhibition of inducible nitric oxide synthesis by the herbal preparation Padma 28 in macrophage cell line.Can J Physiol Pharmacol. 2000;78:861-866.
Wang DF, Shang JY, Yu QH. [Analgesic and anti-inflammatory effects of the flower of Althaea rosea (L.) Cav.].Zhongguo Zhongyao Zazhi. 1989;14:46-48, 64.
Fan AY, Lao L, Zhang RX, Wang LB, Lee DY, Ma ZZ, Zhang WY, Berman B. Effects of an acetone extract of Boswellia carterii Birdw. (Burseraceae) gum resin on rats with persistent inflammation.J Altern Complement Med. 2005;11:323-331.
Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y, Suzuki T. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri.J Ethnopharmacol. 2006;107:249-253.
Kiela PR, Midura AJ, Kuscuoglu N, Jolad SD, Sólyom AM, Besselsen DG, Timmermann BN, Ghishan FK. Effects of Boswellia serrata in mouse models of chemically induced colitis.Am J Physiol Gastrointest Liver Physiol. 2005;288:G798-G808.
Mencarelli A, Renga B, Palladino G, Distrutti E, Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.Biochem Pharmacol. 2009;78:1214-1223.
Cheon JH, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis.Inflamm Bowel Dis. 2006;12:1152-1161.
Birdane FM, Cemek M, Birdane YO, Gülçin I, Büyükokuroğlu ME. Beneficial effects of Foeniculum vulgare on ethanol-induced acute gastric mucosal injury in rats.World J Gastroenterol. 2007;13:607-611.
Choi EM, Hwang JK. Antiinflammatory, analgesic and antioxidant activities of the fruit of Foeniculum vulgare.Fitoterapia. 2004;75:557-565.
Kim HJ, Neophytou C. Natural anti-inflammatory compounds for the management and adjuvant therapy of inflammatory bowel disease and its drug delivery system.Arch Pharm Res. 2009;32:997-1004.
Al-Said MS, Ageel AM, Parmar NS, Tariq M. Evaluation of mastic, a crude drug obtained from Pistacia lentiscus for gastric and duodenal anti-ulcer activity.J Ethnopharmacol. 1986;15:271-278.
Rodríguez-Cabezas ME, Gálvez J, Camuesco D, Lorente MD, Concha A, Martinez-Augustin O, Redondo L, Zarzuelo A. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats.Clin Nutr. 2003;22:463-471.
Rodríguez-Cabezas ME, Gálvez J, Lorente MD, Concha A, Camuesco D, Azzouz S, Osuna A, Redondo L, Zarzuelo A. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats.J Nutr. 2002;132:3263-3271.
Joo HY, Lim K, Lim KT. Phytoglycoprotein (150 kDa) isolated from Solanum nigrum Linne has a preventive effect on dextran sodium sulfate-induced colitis in A/J mouse.J Appl Toxicol. 2009;29:207-213.
Jainu M, Devi CS. Antiulcerogenic and ulcer healing effects of Solanum nigrum (L.) on experimental ulcer models: possible mechanism for the inhibition of acid formation.J Ethnopharmacol. 2006;104:156-163.
Akhtar MS, Munir M. Evaluation of the gastric antiulcerogenic effects of Solanum nigrum, Brassica oleracea and Ocimum basilicum in rats.J Ethnopharmacol. 1989;27:163-176.
Mahesh R, Bhuvana S, Begum VM. Effect of Terminalia chebula aqueous extract on oxidative stress and antioxidant status in the liver and kidney of young and aged rats.Cell Biochem Funct. 2009;27:358-363.
Bhattacharya S, Chaudhuri SR, Chattopadhyay S, Bandyopadhyay SK. Healing Properties of Some Indian Medicinal Plants against Indomethacin-Induced Gastric Ulceration of Rats.J Clin Biochem Nutr. 2007;41:106-114.
Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohnâs
disease treated with mastic.World J Gastroenterol. 2007;13:6031-6036.
Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Chios mastic treatment of patients with active Crohn’s disease.World J Gastroenterol. 2007;13:748-753.
Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, Bästlein E, Wilhelms G, Morgner A, Wigginghaus B. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.Int J Colorectal Dis. 2007;22:1445-1451.
Gupta I, Parihar A, Malhotra P, Gupta S, Lüdtke R, Safayhi H, Ammon HP. Effects of gum resin of Boswellia serrata in patients with chronic colitis.Planta Med. 2001;67:391-395.
Gupta I, Parihar A, Malhotra P, Singh GB, Lüdtke R, Safayhi H, Ammon HP. Effects of Boswellia serrata gum resin in patients with ulcerative colitis.Eur J Med Res. 1997;2:37-43.
Al-Habbal MJ, Al-Habbal Z, Huwez FU. A double-blind controlled clinical trial of mastic and placebo in the treatment of duodenal ulcer.Clin Exp Pharmacol Physiol. 1984;11:541-544.
Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU).Am J Gastroenterol. 1999;94:427-433.